Andrew John (AJ) Rudowitz is a member of the Trial Practice Group, focusing his practice in the areas of antitrust litigation, complex commercial disputes, white-collar criminal defense, non-compete/trade secrets and False Claims Act cases. Mr. Rudowitz has represented clients in the industry areas of Healthcare, Pharmaceuticals, Medical Device Manufacturers, Telecommunications and Construction.
Mr. Rudowitz participates in the firm’s robust Pro Bono Program in the areas of Veterans’ Rights and Juvenile Lifers Without Parole.
Mr. Rudowitz is a 2017 summa cum laude graduate of Temple University, Beasley School of Law, where he was Articles Editor of the Temple Law Review. Mr. Rudowitz graduated from Stonehill College in 2010, with a degree in Business Management. While in law school, Mr. Rudowitz served as a judicial intern for the Honorable Juan Sánchez of the U.S. District Court for the Eastern District of Pennsylvania.
Prior to entering law school, Mr. Rudowitz was a professional basketball player in Germany for four years. He is proficient in written and spoken German.
Representative Matters
Represented Virtua Health System and Our Lady of Lourdes Health System in commercial litigation brought by Deborah Heart & Lung Center in New Jersey state court whereby Deborah claimed that Virtua’s acquisition of Lourdes in 2019 caused Lourdes to breach a restrictive covenant in a contract between Deborah and Lourdes, and resulted in Virtua inducing the alleged breach and competing unfairly with Deborah. This matter was resolved by the mutual agreement of the parties and dismissed in its entirety with prejudice.
Representing former pharmaceutical executive Martin Shkreli in defending against allegations of monopoly maintenance and anticompetitive conduct under the Sherman Act, in Federal Trade Commission, et al. v. Vyera Pharmaceuticals LLC, et al. (S.D.N.Y).
Defending generic pharmaceutical supplier in multidistrict price-fixing cases.
Represented the President of an information technology staffing firm in criminal prosecution for visa fraud and criminal forfeiture.
Represented Otto Bock HealthCare North America, Inc. in FTC investigation and litigation. FTC Docket No. 9378
Successfully represented a U.S. company in an eighteen (18) month hearing before the Pennsylvania Gaming Control Board involving complicated legal issues under the Pennsylvania gaming law, comparison of the regulation of a licensee in Hong Kong with the regulation of a registered investment adviser in the United States, as well as a comparison of the regulation of an investment company in the Cayman Islands with the regulation of an investment company in the United States.
Represented Virtus Pharmaceuticals, a specialty pharmaceutical company, in a recent mediation against a now defunct contract drug manufacturer and its insurers. Recovered all of Virtus' multi-million dollar losses resulting from a national recall of two drugs made by the manufacturer.
Admissions
- Pennsylvania
- U.S. District Court for the Eastern District of Pennsylvania
- U.S. District Court for the Middle District of Pennsylvania
- U.S. District Court for the Southern District of Indiana
Education
- Temple University Beasley School of Law, J.D., summa cum laude, 2017
- Articles Editor, Temple Law Review - Stonehill College, B.A., 2010
Experience
Duane Morris LLP
- Associate, 2017-present- U.S. District Court for the Eastern District of Pennsylvania
- Judicial Intern to the Honorable Juan Sanchez, 2016-2017
Professional Activities
- American Bar Association
- Pennsylvania Bar Asssociation
- Philadelphia Bar Association
Honors and Awards
- Named to Best Lawyers "Ones to Watch," 2023 and 2024
Civic and Charitable Activities
- Volunteer - Child Life Services at Children's Hospital of Philadelphia, February 2022-present
Selected Publications
- Co-author, "FTC Proposes Nationwide, Retroactive Ban on Virtually All Non-Compete Clauses," Duane Morris Alert, January 6, 2023
- Co-author, "SCOTUS Curbs FTC's Enthusiasm by Limiting Relief Available Under Section 13(b) of the FTC Act," Duane Morris Alert, April 27, 2021
Co-author, "FTC Issues Report on Its Authority Under Section 5 of the FTC ACT to Challenge Pharmaceutical Drug Price Increases," Duane Morris Alert, July 16, 2019